These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34624444)

  • 1. An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases.
    Wu HH; Ralph KL; Sepuldeva E; Hansen G; Li H; Huang ZF; Liu D; Dziegelewski M; Ahlberg J; Frego L; Fogal S; van Tongeren S; Grimaldi C; Litzenberger T; Presky D; Singh S; Brodeur S; Kroe-Barrett R
    Int J Pharm; 2021 Nov; 609():121162. PubMed ID: 34624444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients.
    Marken J; Muralidharan S; Giltiay NV
    Arthritis Res Ther; 2021 Jan; 23(1):5. PubMed ID: 33407802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis.
    Ramanujam M; Steffgen J; Visvanathan S; Mohan C; Fine JS; Putterman C
    Autoimmun Rev; 2020 Nov; 19(11):102668. PubMed ID: 32942031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
    Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases.
    Schwabe C; Rosenstock B; Doan T; Hamilton P; Dunbar PR; Eleftheraki AG; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    J Clin Pharmacol; 2018 Dec; 58(12):1566-1577. PubMed ID: 30113724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Immunopharmacologic Assessment of KPL-404, a Novel, Humanized, Non-Depleting Antagonistic Anti-CD40 Monoclonal Antibody.
    Muralidharan S; Njenga M; Garron T; Bondensgaard K; Paolini JF
    J Pharmacol Exp Ther; 2022 Apr; 381(1):12-21. PubMed ID: 35078863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond.
    Karnell JL; Rieder SA; Ettinger R; Kolbeck R
    Adv Drug Deliv Rev; 2019 Feb; 141():92-103. PubMed ID: 30552917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.
    Early GS; Zhao W; Burns CM
    J Immunol; 1996 Oct; 157(7):3159-64. PubMed ID: 8816428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes.
    Meabed MH; Taha GM; Mohamed SO; El-Hadidy KS
    Hematology; 2007 Aug; 12(4):301-7. PubMed ID: 17654056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment.
    Liu MF; Chao SC; Wang CR; Lei HY
    Autoimmunity; 2001; 34(2):107-13. PubMed ID: 11905840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential expression of B7.2 (CD86), but not B7.1 (CD80), on B cells induced by CD40/CD40L interaction is essential for anti-DNA autoantibody production in patients with systemic lupus erythematosus.
    Nagafuchi H; Shimoyama Y; Kashiwakura J; Takeno M; Sakane T; Suzuki N
    Clin Exp Rheumatol; 2003; 21(1):71-7. PubMed ID: 12673892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders.
    Chand Dakal T; Dhabhai B; Agarwal D; Gupta R; Nagda G; Meena AR; Dhakar R; Menon A; Mathur R; Mona ; Yadav V; Sharma A
    Immunobiology; 2020 Mar; 225(2):151899. PubMed ID: 31899051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
    Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
    Front Immunol; 2021; 12():786144. PubMed ID: 35095862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered Cell Membrane Vesicles Expressing CD40 Alleviate System Lupus Nephritis by Intervening B Cell Activation.
    Fang T; Li B; Li M; Zhang Y; Jing Z; Li Y; Xue T; Zhang Z; Fang W; Lin Z; Meng F; Li L; Yang Y; Zhang X; Liang X; Chen SN; Chen J; Zhang X
    Small Methods; 2023 Mar; 7(3):e2200925. PubMed ID: 36605001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.
    Shock A; Burkly L; Wakefield I; Peters C; Garber E; Ferrant J; Taylor FR; Su L; Hsu YM; Hutto D; Amirkhosravi A; Meyer T; Francis J; Malcolm S; Robinson M; Brown D; Shaw S; Foulkes R; Lawson A; Harari O; Bourne T; Maloney A; Weir N
    Arthritis Res Ther; 2015 Sep; 17(1):234. PubMed ID: 26335795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The CD40-CD40L axis: Current and future implications in clinical immunology].
    Vial G; Gensous N; Duffau P
    Rev Med Interne; 2021 Oct; 42(10):722-728. PubMed ID: 33674076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis.
    Tanaka H; Yang GX; Iwakoshi N; Knechtle SJ; Kawata K; Tsuneyama K; Leung P; Coppel RL; Ansari AA; Joh T; Bowlus C; Gershwin ME
    Clin Exp Immunol; 2013 Dec; 174(3):364-71. PubMed ID: 23981074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus.
    Perper SJ; Westmoreland SV; Karman J; Twomey R; Seagal J; Wang R; McRae BL; Clarke SH
    J Immunol; 2019 Jul; 203(1):58-75. PubMed ID: 31109957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway.
    Toubi E; Shoenfeld Y
    Autoimmunity; 2004; 37(6-7):457-64. PubMed ID: 15621572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism.
    Nakamura M; Tanaka Y; Satoh T; Kawai M; Hirakata M; Kaburaki J; Kawakami Y; Ikeda Y; Kuwana M
    Rheumatology (Oxford); 2006 Feb; 45(2):150-6. PubMed ID: 16188945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.